This 2017 study assessed the combined effects of sirolimus (an mTOR inhibitor) and metformin (an AMPK activator) on colon cancer cell lines (HT29, SW620, HCT116) and in a mouse model. The combination treatment (Met/S) significantly inhibited cell viability and tumor growth more than either agent alone. Mechanistically, the combination downregulated
